TGA green-lights diabetes drug for HFpEF
Clinicians are hailing a new indication for empagliflozin as 'a major turning point' in treatment
Doctors can now prescribe empagliflozin to patients with symptomatic heart failure, regardless of left ventricular ejection fraction, in addition to standard therapy.
Last month, the TGA expanded the indication for the SGLT-2 inhibitor beyond management of type 2 diabetes, making it the first drug to be approved for heart failure with preserved ejection fraction (HFpEF).
